We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
23.50 | 1.38% | 1,728.50 | 1,727.50 | 1,728.50 | 1,729.50 | 1,695.50 | 1,705.00 | 6,275,082 | 16:35:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.44 | 71.14B |
Date | Subject | Author | Discuss |
---|---|---|---|
23/4/2015 08:35 | I see that JP Morgan are still suggesting an "underweight" position for GSK with a share price target of 1380p...a 12% fall which at least is consistent with their analysis over the last year or so. On balance the Brokers are still slightly more positive with 9 buys and 7 sells, with the rest neutral (19) at a hold recommendation. Guess much will depend or be influenced by the numerous compounds GSK are advancing but there appears sufficient in the pipe-line to protect the company from more negative comment. | cyberian | |
23/4/2015 08:14 | IN again @ 1545.75 ....... ;0) | tradermichael | |
22/4/2015 17:27 | Bought in big time today at 1544p. I thought it had fallen far enough so wanted to get my new ISA allowance invested before the next XD date. One just cannot take any notice of analysts (not even if they could agree). | jadeticl3 | |
22/4/2015 12:32 | I am no chartist but when I read TM's post I thought, I am not sure, chart looks like 1520p. Will top up if it gets there. | philo124 | |
22/4/2015 11:43 | Well done Woodhawk...the share price should recover although ADR trading may be effected today by the move in London..they closed over in NY at 1581p last night, so a big fall will come, I guess. Expect the results will be OK, as USD rise may have helped matters and the FD was rather convincing that the Div yield will remain strong, however, the market appears less attracted by the yield play at the moment. The latter may change soon with all the uncertainties lying ahead on our political front. Difficult to judge when to add when the fall has happened so rapidly as is often the case...the analysts are all over the place with predictions, but the gloom is a bit overdone by the guys suggesting a weaker trend in future earnings etc. Thoughts of the special B shares and other more positive issues will kick-in once this fall, and the share price finds some stability/support. | cyberian | |
22/4/2015 10:00 | I think one of the key concerns here is that the management are more interested in corporate activity and the day to day performance is perhaps not as good as it should be. Results two weeks today - day before the election. Lets hope its not a good day to bury bad news, and they don't try to cover poor sales with blurb about the special divi or hiving off the jv. | dr biotech | |
22/4/2015 09:55 | Why should one recommendation affect the price so, when there is such a wide spread? In any event, I've just repurchased those I sold at £16.43 a couple of weeks ago, Cyberian. Next ex-divi date in 3 weeks. | woodhawk | |
22/4/2015 09:54 | Thanks...May 6th it is. | cyberian | |
22/4/2015 09:40 | 6th may according to GSK website | mr woodentop | |
22/4/2015 09:33 | Huh!! looks like yet another sell recommendation has spooked GSK before 1Q results, and the market set for a poor/nervous day? I see someone has indicated that !Q results will be on May 8th but this would be about a week later than usual...is this correct? | cyberian | |
20/4/2015 09:18 | Agree, and on all of the above, I'm IN @1582.88 ........ ;0) | tradermichael | |
20/4/2015 09:13 | Very quiet here before the next results due any day I guess...the yield is still very attractive especially taking into account the 80p plus B share matter. Guess if you add-in the commitment of divi policy this year, that would create a return of 11.5%.The potential weakening of the UK pound with election uncertainties will ironically help earnings, and the positive China move yesterday suggests major economies are committed to extend growth, if possible. We have also got the potential IPO spin-off being reviewed urgently by Goldman Sachs and the other 2 investment banks mandated by GSK. A challenging year ahead and beyond but the drive by the company to achieve savings through greater manpower productivity and improved processing will help the bottom line. | cyberian | |
16/4/2015 10:33 | There may be a temporary drop in price, but it accompanies a deal that will give GSK a massive opportunity to consolidate and expand their markets and, as with normal dividends, the price will come back - in this case quite quickly, I suggest. | tradermichael | |
16/4/2015 10:05 | Nik, I will be like any other dividend. So if it pays 80p, then the shares will drop by 80p the day it goes XD. I'd rather they used the money in other ways - reduce debt or buy some smaller companies etc. | dr biotech | |
15/4/2015 22:31 | May explain the drift down this afternoon when the US opened.. "Societe Generale initiated coverage on shares of GlaxoSmithKline plc (NYSE:GSK) in a research note released on Wednesday morning, TheFlyOnTheWall.com reports. The firm issued a sell rating on the stock." | philanderer | |
15/4/2015 17:14 | The Board have clearly stated that there will be a return to shareholders so i would be very surprised if there was anything other than that. | atlantic57 | |
15/4/2015 16:46 | But the big question: will it be accompanied by a share consolidation?? When VOD did this recently, the shareholders (incl myself) were no better off for the so-called special divi. NR | nik rosa | |
15/4/2015 14:33 | A B share scheme is a way a company can return cash to shareholders that also gives all eligible shareholders a choice as to when and how they receive their cash, which is intended to afford UK tax-resident shareholders flexibility in the UK tax treatment of their proceeds. In addition, it treats all shareholders equally relative to the size of their existing shareholdings in the Company. The value and structure of the Capital Return is subject to further due diligence, taking into account factors including the distributable reserves position of the Company and the tax implications for Shareholders. Shareholders will be written to in 2015 when specific details on the B share scheme have been finalised. | tradermichael | |
15/4/2015 13:07 | jadeticl3 Re Shell A & B shares, this is not the same sort of thing at all. The Shell A shares are listed in Amsterdam and the B shares in London. Its all to do with different currencies, different tax treatments etc and far to complex to be discussed! The GSK B shares are just a short term tool to allow investors to choose how to handle the forthcoming distribution. | daveofdevon | |
15/4/2015 12:42 | Will the B shares qualify for a divi? Z | zeppo | |
15/4/2015 12:21 | Do you have a bigger plan - hold for capital growth or hold for dividend income? | tradermichael | |
15/4/2015 11:31 | I am at a bit of a loss gsk have surpassed my origional target price, but should I hold for the dividend? | hanse495 | |
15/4/2015 10:37 | More questions on B shares. Shell shares are listed as A and B shares and appear to be permanently so. Were Shell B shares derived in the way the new GSK B shares will come into play? Will GSK B shares also have an indefinite life? | jadeticl3 | |
15/4/2015 10:09 | Thanks for the replies. | 2hoggy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions